The role and mode of action of apolipoproteins CIII and AV: Synergistic actors in triglyceride metabolism?

Current Opinion in Lipidology

Volumn 15, Issue 3, 2004, Pages 239-246

  Van Dijk, Ko Willems ^a   Rensen, Patrick C N ^a,b   Voshol, Peter J ^a,b   Havekes, Louis M ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Apolipoprotein AV; Apolipoprotein CIII; Triglyceride metabolism

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN C3; TRIACYLGLYCEROL;

CHROMOSOME ANALYSIS; DNA POLYMORPHISM; GENE CLUSTER; GENE CONTROL; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC VARIABILITY; HUMAN; LIPID METABOLISM; MOLECULAR MECHANICS; NONHUMAN; POPULATION; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; STRUCTURE ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; APOLIPOPROTEIN C-III; APOLIPOPROTEINS; APOLIPOPROTEINS A; APOLIPOPROTEINS C; GENE EXPRESSION REGULATION; HUMANS; HYPERTRIGLYCERIDEMIA; LINKAGE (GENETICS); MICE; MUTATION; TRIGLYCERIDES;

HIATUS;

EID: 2642551767     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200406000-00002     Document Type: Review

References (72)

1. Ito Y, Azrolan N, O'Connell A, et al. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 1990; 249:790-793.
2. Maeda N, Li H, Lee D, et al. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem 1994; 269:23610-23616.
3. Pennacchio LA, Olivier M, Hubacek JA, et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001; 294:169-173.
4. Groenendijk M, Cantor RM, de Bruin TW, Dallinga-Thie GM. The apoAI-CIII-AIV gene cluster. Atherosclerosis 2001; 157:1-11.
5. Pennacchio LA, Rubin EM. Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice. Arterioscler Thromb Vasc Biol 2003; 23:529-534. Excellent literature review of genetic associations of APOA5 polymorphisms with plasma triglyceride levels.
6. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3:213-219.
7. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998; 97:1029-1036.
8. Ginsberg HN. Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy. Am J Cardiol 2001; 87:1174-1180.
9. Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts? Circulation 2003; 108:1546-1551. Expert opinion on the pathophysiology of the metabolic syndrome.
10. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 23:201-229.
11. Goudriaan JR, Tacken PJ, Dahlmans VE, et al. Protection from obesity in mice lacking the VLDL receptor. Arterioscler Thromb Vasc Biol 2001; 21:1488-1493.
12. Jong MC, Voshol PJ, Muurling M, et al. Protection from obesity and insulin resistance in mice overexpressing human apolipoprotein C1. Diabetes 2001; 50:2779-2785.
13. Herbert PN, Assmann G, Grotton JAM, Fredrickson DS. Disorders of lipid and lipoprotein metabolism. In: Stanbury JB, Wyngaarden DS, Fredrickson DS, et al., editors. Metabolis basis of inherited disease. New York: McGraw-Hill; 1999. pp. 589-651.
14. Onat A, Hergenc G, Sansoy V, et al. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis 2003; 168:81-89.
15. Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins: effect of apolipoprotein C-III. J Clin Invest 1985; 75:384-390.
16. Ginsberg HN, Le NA, Goldberg IJ, et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI: evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 1986; 78:1287-1295.
17. Liu H, Labeur C, Xu CF, et al. Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr. J Lipid Res 2000; 41:1760-1771.
18. Luttmann S, von Eckardstein A, Wei W, et al. Electrophoretic screening for genetic variation in apolipoprotein C-III: identification of a novel apoC-III variant, apoC-III(Asp45→Asn), in a Turkish patient. J Lipid Res 1994; 35:1431-1440.
19. Maeda H, Hashimoto RK, Ogura T, et al. Molecular cloning of a human apoC-III variant: Thr 74-Ala 74 mutation prevents O-glycosylation. J Lipid Res 1987; 28:1405-1409.
20. Pullinger CR, Malloy MJ, Shahidi AK, et al. A novel apolipoprotein C-III variant, apoC-III(Gln38→Lys), associated with moderate hypertriglyceridemia in a large kindred of Mexican origin. J Lipid Res 1997; 38:1833-1840.
21. von Eckardstein A, Holz H, Sandkamp M, et al. Apolipoprotein C-III(Lys58-Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. J Clin Invest 1991; 87:1724-1731.
22. Roghani A, Zannis VI. Mutagenesis of the glycosylation site of human ApoCIII: O-linked glycosylation is not required for ApoCIII secretion and lipid binding. J Biol Chem 1988; 263:17925-17932.
23. Li WW, Dammerman MM, Smith JD, et al. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 1995; 96:2601-2605.
24. Waterworth DM, Ribalta J, Nicaud V, et al. ApoCIII gene variants modulate postprandial response to both glucose and fat tolerance tests. Circulation 1999; 99:1872-1877.
25. Waterworth DM, Talmud PJ, Luan J, et al. Variants in the APOC3 promoter insulin responsive element modulate insulin secretion and lipids in middle-aged men. Biochim Biophys Acta 2003; 1637:200-206. Description of the association of APOC3 -482C > T and 455T > C polymorphism with insulin sensitivity in middle-aged men but not women.
26. Olivieri O, Bassi A, Stranieri C, et al. Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease. J Lipid Res 2003; 44:2374-2381. Study reporting the association of plasma apoCIII levels and the APOC3 -455T > C SNP with coronary artery disease in metabolic syndrome patients.
27. Couillard C, Vohl MC, Engert JC, et al. Effect of apoC-III gene polymorphisms on the lipoprotein-lipid profile of viscerally obese men. J Lipid Res 2003; 44:986-993. Study reporting the association of the APOC3 3238C > G SNP with plasma triglyceride levels in obese men and the lack of association of the APOC3 -482C > T and 455T > C SNP with glucose sensitivity.
28. Quarfordt SH, Michalopoulos G, Schirmer B. The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat. J Biol Chem 1982; 257:14642-14647.
29. Windler E, Havel RJ. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res 1985; 26:556-565.
30. Sehayek E, Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem 1991; 266:18259-18267.
31. Ebara T, Ramakrishnan R, Steiner G, Shachter NS. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice: apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J Clin Invest 1997; 99:2672-2681.
32. Jong MC, Rensen PC, Dahlmans VE, et al. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J Lipid Res 2001; 42:1578-1585.
33. de Silva HV, Lauer SJ, Wang J, et al. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem 1994; 269:2324-2335.
34. Hirano T, Takahashi T, Saito S, et al. Apoprotein C-III deficiency markedly stimulates triglyceride secretion in vivo: comparison with apoprotein E. Am J Physiol Endocrinol Metab 2001; 281:E665-E669.
35. Segrest JP, Jones MK, De Loof H, et al. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J Lipid Res 1992; 33:141-166.
36. Aalto-Set ala K, Fisher EA, Chen X, et al. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice: diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest 1992; 90:1889-1900.
37. Lambert DA, Catapano AL, Smith LC, et al. Effect of the apolipoprotein C-II/ C-III1 ratio on the capacity of purified milk lipoprotein lipase to hydrolyse triglycerides in monolayer vesicles. Atherosclerosis 1996; 127:205-212.
38. McConathy WJ, Gesquiere JC, Bass H, et al. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res 1992; 33:995-1003.
39. Sparrow JT, Pownall HJ, Hsu FJ, et al. Lipid binding by fragments of apolipoprotein C-III-1 obtained by thrombin cleavage. Biochemistry 1977; 16:5427-5431.
40. Liu H, Talmud PJ, Lins L, et al. Characterization of recombinant wild type and site-directed mutations of apolipoprotein C-III: lipid binding, displacement of ApoE, and inhibition of lipoprotein lipase. Biochemistry 2000; 39:9201-9212.
41. Lins L, Flore C, Chapelle L, et al. Lipid-interacting properties of the N-terminal domain of human apolipoprotein C-III. Protein Eng 2002; 15:513-520.
42. Zannis VI, Kan HY, Kritis A, et al. Transcriptional regulatory mechanisms of the human apolipoprotein genes in vitro and in vivo. Curr Opin Lipidol 2001; 12:181-207.
43. Hertz R, Bishara-Shieban J, Bar-Tana J. Mode of action of peroxisome proliferators as hypolipidemic drugs: suppression of apolipoprotein C-III. J Biol Chem 1995; 270:13470-13475.
44. Staels B, Vu-Dac N, Kosykh VA, et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase: a potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 1995; 95:705-712.
45. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996; 15:5336-5348.
46. Coste H, Rodriguez JC. Orphan nuclear hormone receptor Rev-erbalpha regulates the human apolipoprotein CIII promoter. J Biol Chem 2002; 277:27120-27129.
47. Raspe E, Duez H, Gervois P, et al. Transcriptional regulation of apolipoprotein C-III gene expression by the orphan nuclear receptor RORalpha. J Biol Chem 2001; 276:2865-2871.
48. Raspe E, Duez H, Mansen A, et al. Identification of Rev-erbalpha as a physiological repressor of apoC-III gene transcription. J Lipid Res 2002; 43:2172-2179.
49. Gervois P, Chopin-Delannoy S, Fadel A, et al. Fibrates increase human REV-ERBalpha expression in liver via a novel peroxisome proliferator-activated receptor response element. Mol Endocrinol 1999; 13:400-409.
50. van der Vliet HN, Sammels MG, Leegwater ACJ, et al. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem 2001; 276:44512-44520.
51. Pennacchio LA, Olivier M, Hubacek JA, et al. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet 2002; 11:3031-3038.
52. Kao JT, Wen HC, Chien KL, et al. A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum Mol Genet 2003; 12:2533-2539. Identification of the potentially functional apoAV variant G185C in a Chinese population.
53. Weinberg RB, Cook VR, Beckstead JA, et al. Structure and interfacial properties of human apolipoprotein A-V. J Biol Chem 2003; 278:34438-34444. Excellent description of the properties of apoAV, based on both computer analysis and physicochemical analysis. The hypothesis is put forward that apoAV may function to inhibit VLDL secretion.
54. Nielsen H, Engelbrecht J, Brunak S, von Heijne G. A neural network method for identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. Int J Neural Syst 1997; 8:581-599.
55. Kozak M. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 1986; 44:283-292.
56. Kozak M. Recognition of AUG and alternative initiator codons is augmented by G in position +4 but is not generally affected by the nucleotides in positions +5 and +6. EMBO J 1997; 16:2482-2492.
57. Kozak M. An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 1987; 15:8125-8148.
58. Prieur X, Coste H, Rodriguez JC. The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-alpha and contains a novel farnesoid X-activated receptor response element. J Biol Chem 2003; 278:25468-25480. Excellent study reporting the regulation of APOA5 by PPARα.
59. van der Vliet HN, Schaap FG, Levels JHM, et al. Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem Biophys Res Commun 2002; 295:1156-1159.
60. Beckstead JA, Oda MN, Martin DDO, et al. Structure-function studies of human apolipoprotein A-V: a regulator of plasma lipid homeostasis. Biochemistry 2003; 42:9416-9423. Structure-functional analysis of recombinant apoAV and report of the inability of apoAV to function as cholesterol acceptor and activator of lecithin-cholesterol acyltransferase.
61. Schaap FG, Voshol PJ, Rensen PC, et al. Apolipoprotein AV expression ameliorates type III hyperlipidemia in mouse models by stimulating lipoprotein lipase-mediated VLDL-triglyceride hydrolysis. Circulation 2003; 108:257.
62. Vu-Dac N, Gervois P, Jakel H, et al. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem 2003; 278:17982-17985. Report describing the PPARα responsiveness and isolation of the promoter element of APOA5.
63. Baum L, Tomlinson B, Thomas GN. APOA5-1131T > C polymorphism is associated with triglyceride levels in Chinese men. Clin Genet 2003; 63:377-379.
64. Martin S, Nicaud V, Humphries SE, Talmud PJ. Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges. Biochim Biophys Acta 2003; 1637:217-225. Study describing the association of APOA5 variants with plasma triglyceride levels but not the response to a fat load in healthy young men. An intergenic SNP (-12238T > C) was found to be associated with the response to an oral glucose test.
65. Nabika T, Nasreen S, Kobayashi S, Masuda J. The genetic effect of the apoprotein AV gene on the serum triglyceride level in Japanese. Atherosclerosis 2002; 165:201-204.
66. Aouizerat BE, Kulkarni M, Heilbron D, et al. Genetic analysis of a polymorphism in the human apoA-V gene: effect on plasma lipids. J Lipid Res 2003; 44:1167-1173.
67. Masana L, Ribalta J, Salazar J, et al. The apolipoprotein AV gene and diurnal triglyceridaemia in normolipidaemic subjects. Clin Chem Lab Med 2003; 41:517-521.
68. Horinek A, Vrablik M, Ceska R, et al. T-1131→C polymorphism within the apolipoprotein AV gene in hypertriglyceridernic individuals. Atherosclerosis 2003; 167:369-370.
69. Eichenbaum-Voline S, Olivier M, Jones EL, et al. Linkage and association between distinct variants of the APOA1/C3/A4/A5 gene cluster and familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2004; 24:167-74. Excellent (haplotype) analysis of the contribution of variation in the APOC3 and A5 genes to familial combined hyperlipidemia.
70. Evans D, Buchwald A, Beil FU. The single nucleotide polymorphism -1131T > C in the apolipoprotein A5 (APOA5) gene is associated with elevated triglycerides in patients with hyperlipidemia. J Mol Med 2003; 81:645-654.
71. Talmud PJ, Hawe E, Martin S, et al. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet 2002; 11:3039-3046.
72. Teusink B, Voshol PJ, Dahlmans VE, et al. Contribution of fatty acids released from lipolysis of plasma triglycerides to total plasma fatty acid flux and tissue-specific fatty acid uptake. Diabetes 2003; 52:614-620. Quantitative analysis of the fate of fatty acids derived from triglyceride and fatty acids present in plasma. Evidence is presented that they represent a communal pool.